Efficacia del sistema di stimolazione modulare EMPOWER™ e dell'ICD sottocutaneo EMBLEM™ per comunicare la stimolazione antitachicardica (MODULAR ATP)
The MODULAR ATP Clinical Study is designed to demonstrate safety, performance, and effectiveness of the Modular Cardiac Rhythm Management (mCRM) Therapy System.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The MODULAR ATP Clinical Study will enroll subjects with a standard Implantable Cardioverter Defibrillator (ICD) indication applying international practice guidelines, as well as those who already have an implanted S-ICD System and satisfy the inclusion criteria for this study, while not meeting any exclusion criteria. Subjects will be followed for at least 6 months following mCRM Therapy System implantation.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Linz, Austria
- Kepler Universitaetsklinikum
-
-
-
-
-
Québec, Canada
- Institut Universitaire de Cardilogie et Pnuemologie de Quebec (IUCPQ)
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Institut de Cardiologie de Quebec (Montreal Heart)
-
-
-
-
-
Prague, Cechia
- Na Homolce Hospital
-
-
-
-
-
Grenoble, Francia
- CHU Grenoble - Hospital Michallon
-
Lille, Francia, 59000
- CHRU de Lille
-
Nantes, Francia
- CHU de Nantes-Hopital Laennec
-
Paris, Francia
- Hospital European Georges-Pompidou
-
-
-
-
-
Brescia, Italia
- Spedali Civil di Brescia
-
Cotignola, Italia
- Maria Cecilia Hospital SPA
-
Naples, Italia, 80131
- AZ Osp Monaldi
-
Pisa, Italia, 56126
- Azienda Ospedaliero Universitaria Pisana
-
-
-
-
-
Amsterdam, Olanda
- Amsterdam University Medical Center
-
Nieuwegein, Olanda
- St. Antonius Ziekenhuis
-
Rotterdam, Olanda, 3015 CE
- Erasmus MC University Medical Center
-
-
-
-
-
Leeds, Regno Unito, LS1 EX
- The General Infirmary
-
Liverpool, Regno Unito, L14 3PE
- Liverpool Heart and Chest Hospital
-
Manchester, Regno Unito, M13 9WL
- Manchester Heart Center
-
Southampton, Regno Unito
- Southampton University Hospital
-
-
-
-
-
Barcelona, Spagna, 08036
- Hospital Clinic of Barcelona
-
-
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85006
- Banner University Medical Center Phoenix
-
Scottsdale, Arizona, Stati Uniti, 84258
- Scottsdale Healthcare - Shea
-
-
Arkansas
-
Jonesboro, Arkansas, Stati Uniti, 72401
- Arrhythmia Research Group
-
-
Florida
-
Orlando, Florida, Stati Uniti, 32803
- AdventHealth Orlando
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30308
- Emory University Hospital
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40503
- Baptist Health Lexington
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Mayo Clinic
-
-
New Jersey
-
Camden, New Jersey, Stati Uniti, 08103
- Cooper Hospital - University Medical Center
-
-
New York
-
Manhasset, New York, Stati Uniti, 11030
- Northwell University Hospital
-
New York, New York, Stati Uniti, 10029
- Mount Sinai Medical Center
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44195
- Cleveland Clinic
-
Columbus, Ohio, Stati Uniti, 43210
- Ohio State University Medical Center
-
Columbus, Ohio, Stati Uniti, 43214
- Ohio Health Research Institute
-
-
Pennsylvania
-
Hershey, Pennsylvania, Stati Uniti, 17033
- Penn State Health Milton S. Hershey Medical Center
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Hospital of the University of Pennsylvania
-
-
Tennessee
-
Chattanooga, Tennessee, Stati Uniti, 37403
- Erlanger Medical Center
-
-
Virginia
-
Norfolk, Virginia, Stati Uniti, 23507
- Sentara Norfolk General
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98195
- University of Washington Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Patient who meets Class I, IIa, or IIb guideline ICD indications[i],[ii], or who has an existing TV-ICD[iii] or S-ICD[iv]
-
Patient who is deemed to be at risk for MVT based on at least ONE of the following:
- History of Non-Sustained MVT with LVEF ≤ 50%
- History of sustained VT/VF (secondary prevention) with LVEF ≤ 50% or significant cardiac scar*
- History of syncope deemed to be arrhythmic in origin
- History of ischemic cardiomyopathy with LVEF ≤35%
- History of non-ischemic cardiomyopathy with LVEF ≤35% and significant scar*
-
Patient who is willing and capable of providing informed consent (which is not to include the use of a legally authorized representative (LAR) for documentation of informed consent) and participating in all testing associated with this investigation at an approved study site and at the intervals defined by this protocol
-
Patient who is age 18 years or above, or of legal age to give informed consent specific to state and national law
Exclusion Criteria:
-
Patient with an ongoing complication due to Cardiac Implantable Electronic Device (CIED) infection or CIED explant
-
Transvenous lead remnants within the heart from a previously implanted CIED (Note: transvenous lead remnants outside the heart (e.g., in the SVC) are allowed)
-
Patient with a known LA thrombus
-
Patient with a ventricular arrhythmia due to a reversible cause
-
Patient indicated for implantation of a dual chamber pacemaker or cardiac resynchronization therapy (CRT)
-
Patient with another implanted medical device that could interfere with implant of the leadless pacemaker, such as an implanted inferior vena cava filter or mechanical tricuspid heart valve
-
Patient requires rate-responsive pacing therapy
-
Patient is entirely pacemaker-dependent (defined as escape rhythm ≤ 30 bpm)
-
Patient with Acute Coronary Syndrome (i.e. Acute Myocardial Infarction, Unstable Angina) within 40 days
-
Inability to access femoral vein with a 21-French or larger inner diameter introducer sheath due to known anatomy condition, recent surgery, and/ or other relevant condition
-
Patient who has an active implanted electronic medical device intended for chronic use concomitantly with the study system, such as a left ventricular assist device (LVAD). Note that a temporary pacing wire is allowed.
-
Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)
-
Patient with a known cardiovascular anatomy that precludes implant in the right ventricle
-
Patient with a known allergy to any system components
-
Patient with a known or suspected intolerance to S-ICD conversion testing, based on physician discretion
-
Patient is not likely to have meaningful survival** for at least 12 months (documented or per investigator's discretion)
-
Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/ registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.
-
Patient who is a woman of childbearing potential who is known to be pregnant at the time of study enrollment (method of assessment upon investigator's discretion)
[i]Al-Khatib, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. (2018); 138:e272-e391.
[ii] 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). European Heart Journal (2015) 36, 2793-2867.
[iii] TV-ICD system is expected to be fully explanted during or prior to full Coordinated System implant
[iv] Potential subjects with a Model 1010 S-ICD Pulse Generator are only eligible for MODULAR ATP if they are getting upgraded to Model A209, A219 or future BSC S-ICD Pulse Generator; Patients with an existing S-ICD PG subject to the electrical overstress field action are only eligible for MODULAR ATP if they are getting a new BSC Model A209 or A219, or future BSC S-ICD Pulse Generator
*Significant cardiac scar is defined as a scar involving at least one ventricular myocardial segment (i.e., basal infero-septum) as identified in the official findings of a cMRI, or nuclear viability study, or echo report by the interpreting radiologist/ cardiologist who is not affiliated with the study
**meaningful survival means that a patient has a reasonable quality of life and functional status
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: MODULAR ATP Study Participants
All subjects that signed the informed consent were included. Patients consented to receive the mCRM Therapy System which consists of the EMPOWER Leadless Pacemaker and an EMBLEM S-ICD upgraded with investigational firmware. |
Communication testing between S-ICD and LCP in 4 body postures as well as required electrical testing.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Safety Endpoint 1: Percentage of Subjects Without Major EMPOWER MPS System- or Procedure-Related Complications Through 6 Months
Lasso di tempo: Implant through 6 Months Post-Implant
|
Major EMPOWER MPS System- and Procedure-related Complication-Free Rate Subjects will be assessed for safety issues related to the procedure or system through 6 months post implant |
Implant through 6 Months Post-Implant
|
|
Safety Endpoint 2: Percentage of Subjects Without Major EMPOWER MPS System- or Procedure-Related Complications Through 12 Months
Lasso di tempo: Implant through 12 Months Post-Implant
|
Major EMPOWER MPS System- and Procedure-related Complication-free Rate Subjects will be assessed for safety issues related to the procedure or system through 12 months post implant |
Implant through 12 Months Post-Implant
|
|
Primary Effectiveness Endpoint 1: Percentage of Body Postures With Communication Success Between the S-ICD and EMPOWER PG
Lasso di tempo: At the 6 Month Follow-up
|
Communication Success between the S-ICD and EMPOWER PG Data from subjects will be assessed for effectiveness of communication between S-ICD and the EMPOWER PG by evaluating if a paced beat is present during communication testing in four postures: upright, supine, and right and left side. |
At the 6 Month Follow-up
|
|
Primary Effectiveness Endpoint 2: Percentage of Subjects Classified as a Pacing Capture Threshold (PCT) Responder
Lasso di tempo: At the 6 Month Follow-up
|
Proportion of Subjects with Adequate Pacing Capture Threshold Effectiveness will be confirmed by evaluating the percentage of subjects considered to be a PCT Responder, defined as a subject with a PCT measurement of ≤ 2.0 V @ 0.4 ms pulse width |
At the 6 Month Follow-up
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Secondary Effectiveness Endpoint: Subject-specific Slope of EMPOWER PG Sensor-Indicated Rate to the Subject's Workload on Treadmill Test
Lasso di tempo: At the 3 Month Visit
|
Metabolic-Chronotropic Relation Slope (MCR Slope) from the Kay-Wilkoff Model Using the Kay-Wilkoff model, data will be assessed to evaluate the proportionality of the EMPOWER PG's sensor-indicated rate to the subject's workload during the treadmill test |
At the 3 Month Visit
|
|
Secondary Safety Endpoint
Lasso di tempo: Implant through 2 years post-implant
|
All-Cause Survival; data not reported as it is still being collected |
Implant through 2 years post-implant
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Reinoud Knops, MD, PhD, Amsterdam University Medical Centre
- Investigatore principale: Lluis Mont, MD, PhD, Hospital Clinic, University of Barcelona
- Investigatore principale: Vivek Reddy, MD, The Mount Sinai Hospital
- Investigatore principale: Michael Lloyd, MD, Emory University
Pubblicazioni e link utili
Pubblicazioni generali
- Lloyd MS, Brisben AJ, Reddy VY, Blomstrom-Lundqvist C, Boersma LVA, Bongiorni MG, Burke MC, Cantillon DJ, Doshi R, Friedman PA, Gras D, Kutalek SP, Neuzil P, Roberts PR, Wright DJ, Appl U, West J, Carter N, Stein KM, Mont L, Knops RE. Design and rationale of the MODULAR ATP global clinical trial: A novel intercommunicative leadless pacing system and the subcutaneous implantable cardioverter-defibrillator. Heart Rhythm O2. 2023 Jun 2;4(7):448-456. doi: 10.1016/j.hroo.2023.05.004. eCollection 2023 Jul.
- Knops RE, Lloyd MS, Roberts PR, Wright DJ, Boersma LVA, Doshi R, Friedman PA, Neuzil P, Blomstrom-Lundqvist C, Bongiorni MG, Burke MC, Gras D, Kutalek SP, Amin AK, Fu EY, Epstein LM, Tolosana JM, Callahan TD, Aasbo JD, Augostini R, Manyam H, Nair DG, Mondesert B, Su WW, Pepper C, Miller MA, Grammes J, Saleh K, Marquie C, Merchant FM, Cha YM, Cunnington C, Frankel DS, West J, Matznick E, Swackhamer B, Brisben AJ, Weinstock J, Stein KM, Reddy VY, Mont L; MODULAR ATP Investigators. A Modular Communicative Leadless Pacing-Defibrillator System. N Engl J Med. 2024 Oct 17;391(15):1402-1412. doi: 10.1056/NEJMoa2401807. Epub 2024 May 18.
- Lloyd MS, Reddy VY, Roberts P, Doshi RN, Wright DL, Boersma LVA, Friedman PA, Neuzil P, Blomstrom-Lundqvist C, Bongiorni MG, Burke MC, Gras D, Kutalek SP, Marijon E, Tolosana JM, Amin AK, Epstein LM, Aasbo JD, Callahan TD, Brisben AJ, West J, Matznick E, Speakman B, Bachman TN, Mont L, Knops RE. One-Year Outcomes of the MODULAR ATP Trial: A Novel Leadless Pacemaker in Wireless Communication With a Subcutaneous Implantable Cardioverter Defibrillator. Circ Arrhythm Electrophysiol. 2026 Jan;19(1):e014395. doi: 10.1161/CIRCEP.125.014395. Epub 2025 Nov 13.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- C1907
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
There is no plan to share IPD with other researchers in this study.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .